ABSTRACT
Ginseng, a popular herbal supplement among athletes, is believed to enhance exercise capacity and performance. This study investigated the short-term effects of Panax ginseng extract (PG) on aerobic capacity, lipid profile, and cytokines. In a 14-day randomized, double-blind trial, male participants took 500 mg of PG daily. Two experiments were conducted: one in 10 km races (n = 31) and another in a laboratory-controlled aerobic capacity test (n = 20). Blood lipid and cytokine profile, ventilation, oxygen consumption, hemodynamic and fatigue parameters, and race time were evaluated. PG supplementation led to reduced total blood lipid levels, particularly in triacylglycerides (10 km races -7.5 mg/dL (95% CI -42 to 28); sub-maximal aerobic test -14.2 mg/dL (95% CI -52 to 23)), while post-exercise blood IL-10 levels were increased (10 km 34.0 pg/mL (95% CI -2.1 to 70.1); sub-maximal aerobic test 4.1 pg/mL (95% CI -2.8 to 11.0)), and oxygen consumption decreased during the sub-maximal aerobic test (VO2: -1.4 mL/min/kg (95% CI -5.8 to -0.6)). No significant differences were noted in race time, hemodynamic, or fatigue parameters. Overall, PG supplementation for 2 weeks showed benefits in blood lipid profile and energy consumption during exercise among recreational athletes. This suggests a potential role for PG in enhancing exercise performance and metabolic health in this population.
Subject(s)
Athletes , Dietary Supplements , Exercise , Oxygen Consumption , Panax , Plant Extracts , Triglycerides , Humans , Male , Panax/chemistry , Plant Extracts/pharmacology , Plant Extracts/administration & dosage , Adult , Oxygen Consumption/drug effects , Triglycerides/blood , Double-Blind Method , Young Adult , Fasting/bloodABSTRACT
The fatty acid elongase elongation of very long-chain fatty acids protein 2 (ELOVL2) controls the elongation of polyunsaturated fatty acids (PUFA) producing precursors for omega-3, docosahexaenoic acid (DHA), and omega-6, docosapentaenoic acid (DPAn-6) in vivo. Expectedly, Elovl2-ablation drastically reduced the DHA and DPAn-6 in liver mitochondrial membranes. Unexpectedly, however, total PUFAs levels decreased further than could be explained by Elovl2 ablation. The lipid peroxidation process was not involved in PUFAs reduction since malondialdehyde-lysine (MDAL) and other oxidative stress biomarkers were not enhanced. The content of mitochondrial respiratory chain proteins remained unchanged. Still, membrane remodeling was associated with the high voltage-dependent anion channel (VDAC) and adenine nucleotide translocase 2 (ANT2), a possible reflection of the increased demand on phospholipid transport to the mitochondria. Mitochondrial function was impaired despite preserved content of the respiratory chain proteins and the absence of oxidative damage. Oligomycin-insensitive oxygen consumption increased, and coefficients of respiratory control were reduced by 50%. The mitochondria became very sensitive to fatty acid-induced uncoupling and permeabilization, where ANT2 is involved. Mitochondrial volume and number of peroxisomes increased as revealed by transmission electron microscopy. In conclusion, the results imply that endogenous DHA production is vital for the normal function of mouse liver mitochondria and could be relevant not only for mice but also for human metabolism.
Subject(s)
Mitochondria, Liver , Mitochondrial Membranes , Animals , Fatty Acids , Liver , Mice , MitochondriaABSTRACT
AIMS: Mitochondrial dysfunction and inflammation are at the core of axonal degeneration in several multifactorial neurodegenerative diseases, including multiple sclerosis, Alzheimer's disease, and Parkinson's disease. The transcriptional coregulator RIP140/NRIP1 (receptor-interacting protein 140) modulates these functions in liver and adipose tissue, but its role in the nervous system remains unexplored. Here, we investigated the impact of RIP140 in the Abcd1- mouse model of X-linked adrenoleukodystrophy (X-ALD), a genetic model of chronic axonopathy involving the convergence of redox imbalance, bioenergetic failure, and chronic inflammation. METHODS AND RESULTS: We provide evidence that RIP140 is modulated through a redox-dependent mechanism driven by very long-chain fatty acids (VLCFAs), the levels of which are increased in X-ALD. Genetic inactivation of RIP140 prevented mitochondrial depletion and dysfunction, bioenergetic failure, inflammatory dysregulation, axonal degeneration and associated locomotor disabilities in vivo in X-ALD mouse models. CONCLUSIONS: Together, these findings show that aberrant overactivation of RIP140 promotes neurodegeneration in X-ALD, underscoring its potential as a therapeutic target for X-ALD and other neurodegenerative disorders that present with metabolic and inflammatory dyshomeostasis.
Subject(s)
Adrenoleukodystrophy , ATP Binding Cassette Transporter, Subfamily D, Member 1/metabolism , ATP-Binding Cassette Transporters/genetics , ATP-Binding Cassette Transporters/metabolism , ATP-Binding Cassette Transporters/therapeutic use , Adrenoleukodystrophy/genetics , Adrenoleukodystrophy/metabolism , Animals , Disease Models, Animal , Homeostasis , Mice , Mitochondria/metabolism , Nuclear Receptor Interacting Protein 1ABSTRACT
PURPOSE: HFpEF (heart failure with preserved ejection fraction) is a major consequence of diabetic cardiomyopathy with no effective treatments. Here, we have characterized Akita mice as a preclinical model of HFpEF and used it to confirm the therapeutic efficacy of the mitochondria-targeted dicarbonyl scavenger, MitoGamide. METHODS AND RESULTS: A longitudinal echocardiographic analysis confirmed that Akita mice develop diastolic dysfunction with reduced E peak velocity, E/A ratio and extended isovolumetric relaxation time (IVRT), while the systolic function remains comparable with wild-type mice. The myocardium of Akita mice had a decreased ATP/ADP ratio, elevated mitochondrial oxidative stress and increased organelle density, compared with that of wild-type mice. MitoGamide, a mitochondria-targeted 1,2-dicarbonyl scavenger, exhibited good stability in vivo, uptake into cells and mitochondria and reactivity with dicarbonyls. Treatment of Akita mice with MitoGamide for 12 weeks significantly improved the E/A ratio compared with the vehicle-treated group. CONCLUSION: Our work confirms that the Akita mouse model of diabetes replicates key clinical features of diabetic HFpEF, including cardiac and mitochondrial dysfunction. Furthermore, in this independent study, MitoGamide treatment improved diastolic function in Akita mice.
Subject(s)
Benzamides/pharmacology , Cardiovascular Agents/pharmacology , Diabetic Cardiomyopathies/prevention & control , Heart Failure/prevention & control , Stroke Volume/drug effects , Ventricular Dysfunction, Left/prevention & control , Ventricular Function, Left/drug effects , Animals , Diabetic Cardiomyopathies/metabolism , Diabetic Cardiomyopathies/physiopathology , Disease Models, Animal , Glycation End Products, Advanced/metabolism , Heart Failure/metabolism , Heart Failure/physiopathology , Male , Mice, Inbred C57BL , Mice, Mutant Strains , Mitochondria, Heart/drug effects , Mitochondria, Heart/metabolism , Ventricular Dysfunction, Left/metabolism , Ventricular Dysfunction, Left/physiopathologyABSTRACT
Species longevity varies significantly across animal species, but the underlying molecular mechanisms remain poorly understood. Recent studies and omics approaches suggest that phenotypic traits of longevity could converge in the mammalian target of rapamycin (mTOR) signalling pathway. The present study focuses on the comparative approach in heart tissue from 8 mammalian species with a ML ranging from 3.5 to 46 years. Gene expression, protein content, and concentration of regulatory metabolites of the mTOR complex 1 (mTORC1) were measured using droplet digital PCR, western blot, and mass spectrometry, respectively. Our results demonstrate (1) the existence of differences in species-specific gene expression and protein content of mTORC1, (2) that the achievement of a high longevity phenotype correlates with decreased and inhibited mTORC1, (3) a decreased content of mTORC1 activators in long-lived animals, and (4) that these differences are independent of phylogeny. Our findings, taken together, support an important role for mTORC1 downregulation in the evolution of long-lived mammals.
Subject(s)
Adaptor Proteins, Signal Transducing , Longevity , Adaptor Proteins, Signal Transducing/metabolism , Animals , Gene Expression , Longevity/genetics , Mechanistic Target of Rapamycin Complex 1/genetics , Phosphorylation , Regulatory-Associated Protein of mTOR/genetics , Regulatory-Associated Protein of mTOR/metabolism , Sirolimus , TOR Serine-Threonine Kinases/genetics , TOR Serine-Threonine Kinases/metabolismABSTRACT
Mitochondrial reactive oxygen species (ROS) production, specifically at complex I (Cx I), has been widely suggested to be one of the determinants of species longevity. The present study follows a comparative approach to analyse complex I in heart tissue from 8 mammalian species with a longevity ranging from 3.5 to 46 years. Gene expression and protein content of selected Cx I subunits were analysed using droplet digital PCR (ddPCR) and western blot, respectively. Our results demonstrate: 1) the existence of species-specific differences in gene expression and protein content of Cx I in relation to longevity; 2) the achievement of a longevity phenotype is associated with low protein abundance of subunits NDUFV2 and NDUFS4 from the matrix hydrophilic domain of Cx I; and 3) long-lived mammals show also lower levels of VDAC (voltage-dependent anion channel) amount. These differences could be associated with the lower mitochondrial ROS production and slower aging rate of long-lived animals and, unexpectedly, with a low content of the mitochondrial permeability transition pore in these species.
Subject(s)
Electron Transport Complex I , Longevity , Animals , Electron Transport Complex I/genetics , Electron Transport Complex I/metabolism , Longevity/genetics , Mammals/metabolism , Mitochondria/genetics , Mitochondria/metabolism , Reactive Oxygen Species/metabolismABSTRACT
Metformin is one of the treatments used for PCOS pathology decreasing body weight, plasma androgen, FSH and glucose levels. Unfortunately, there is little known about metformin's effects on lipid metabolism, a crucial process in PCOS pathology. We have employed a lipidomic approach to explore alterations in the plasma lipid profile of patients with PCOS following metformin treatment. The aim is to offer new insights about the effect of metformin in PCOS patients. Plasma samples were obtained from 27 subjects prior to and following 12 weeks of metformin treatment. A detailed biochemical characterization and lipidomic profile was performed. Metformin reduces BMI, HOMA-IR, FSH and androstenedione and increases DHEA-S but no changes were found in glucose levels after treatment. Multivariate statistics revealed a specific lipidomic signature due to the effect of 12 weeks of metformin treatment in PCOS patients. This signature includes changes in sphingolipid metabolism suggesting a crosstalk between these lipid species and the androgenic metabolism and a decrease in oxidized lipids reinforcing that metformin treatment improves oxidative stress status. Our study confirms the specific effect of metformin in lipid metabolism on women with PCOS after 12 weeks of treatment.
Subject(s)
Metformin/administration & dosage , Oxidative Stress/drug effects , Polycystic Ovary Syndrome , Sphingolipids/blood , Female , Humans , Oxidation-Reduction/drug effects , Polycystic Ovary Syndrome/blood , Polycystic Ovary Syndrome/drug therapyABSTRACT
Mitochondria have been increasingly recognized as a central regulatory nexus for multiple metabolic pathways, in addition to ATP production via oxidative phosphorylation (OXPHOS). Here we show that inducing mitochondrial DNA (mtDNA) stress in Drosophila using a mitochondrially-targeted Type I restriction endonuclease (mtEcoBI) results in unexpected metabolic reprogramming in adult flies, distinct from effects on OXPHOS. Carbohydrate utilization was repressed, with catabolism shifted towards lipid oxidation, accompanied by elevated serine synthesis. Cleavage and translocation, the two modes of mtEcoBI action, repressed carbohydrate rmetabolism via two different mechanisms. DNA cleavage activity induced a type II diabetes-like phenotype involving deactivation of Akt kinase and inhibition of pyruvate dehydrogenase, whilst translocation decreased post-translational protein acetylation by cytonuclear depletion of acetyl-CoA (AcCoA). The associated decrease in the concentrations of ketogenic amino acids also produced downstream effects on physiology and behavior, attributable to decreased neurotransmitter levels. We thus provide evidence for novel signaling pathways connecting mtDNA to metabolism, distinct from its role in supporting OXPHOS.
Subject(s)
Cellular Reprogramming/genetics , DNA, Mitochondrial/genetics , Diabetes Mellitus, Type 2/genetics , Mitochondria/genetics , Adenosine Triphosphate/genetics , Animals , Carbohydrate Metabolism/genetics , Carbohydrates/genetics , DNA Restriction Enzymes/genetics , Diabetes Mellitus, Type 2/metabolism , Drosophila melanogaster/genetics , Drosophila melanogaster/metabolism , Humans , Metabolic Networks and Pathways/genetics , Mitochondria/metabolism , Oxidative Phosphorylation , Oxidative Stress/geneticsABSTRACT
OBJECTIVE: The aim of this study was to investigate the usefulness of Alzheimer's disease Cerebrospinal Fluid (CSF) biomarkers in predicting the progression to dementia in patients with Mild Cognitive Impairment (MCI). METHODS: One hundred and thirteen patients were consecutively recruited from April 2012 to April 2014. Measurement of CSF biomarkers (amyloid-ß42 (Aß42), total tau (t-tau) and phosphorylated tau (p-tau)) and a neuropsychological evaluation were performed for all patients. We categorized patients with MCI as A+A- and N+N- based on the presence/absence of amyloid pathology and neurodegeneration, respectively. RESULTS: Of 72 patients with MCI, 26 (36%) progressed to dementia. These patients had lower CSF Aß42 levels and higher p-tau and t-tau levels at baseline. The proportion that progressed to dementia was 14.3% (2/14), 36.8% (7/19), 66.7% (4/6) and 75% (12/16) in the A-N-, A+N-, A-N+ (SNAP), and A+N+ patients, respectively (p < 0.05). There were significant differences in the probability of progression from amnestic MCI (aMCI) to AD between the A+N+ and A-N- patients (OR = 8.1, 95% CI 1.5-42.3, p = 0.001) but not between SNAP (OR = 7.3, 95% CI 0.9-61, p = 0.02) or A+N- (OR = 2.1, 95% CI 0.4 to 10.4, p = 0.15) patients compared to the A-N- subgroup. None of the biomarker profiles of the subgroups predicted the time until the progression to AD. CONCLUSION: The use of CSF AD biomarkers in clinical practice improves the certainty of diagnosis and prognosis of patients, especially in patients in the prodromal phase or in patients with atypical presentations.
Subject(s)
Alzheimer Disease/diagnosis , Alzheimer Disease/epidemiology , Cognitive Dysfunction/diagnosis , Cognitive Dysfunction/epidemiology , Disease Progression , Aged , Aged, 80 and over , Alzheimer Disease/cerebrospinal fluid , Amyloid beta-Peptides/metabolism , Biomarkers/analysis , Cognitive Dysfunction/cerebrospinal fluid , Cohort Studies , Female , Humans , Incidence , Male , Neuropsychological Tests , Peptide Fragments/metabolism , Predictive Value of Tests , Prognosis , Retrospective Studies , tau Proteins/metabolismABSTRACT
ETHNOPHARMACOLOGICAL RELEVANCE: Ginseng is a widely used ingredient in several traditional Chinese medicine formulation, mainly as a prophylactic and restorative agent. Ginseng's Chinese traditional formulations have shown protective effects against atherosclerosis, suggesting that ginseng may be useful for the treatment of metabolic disorders. AIM OF THE STUDY: To evaluate whether the supplementation with Panax ginseng (PG) has an effect on blood lipid profile in humans. MATERIALS AND METHODS: A meta-analysis and a systematic review were conducted to evaluate the effects of PG on blood lipid profile. RESULTS: A total of 18 studies met the inclusion criteria, from which 10 studies were performed in volunteers with at least one component of metabolic syndrome, 3 in postmenopausal women, 2 in healthy volunteers and 3 with other types of inclusion criteria. The doses employed ranged from 0.2 to 20â¯g/day (median 3â¯g/day, 95% CI 1.7, 5.8), while the treatment time ranged from 2 to 12 weeks (median 8 weeks, 95% CI 6, 9). Few studies reported the composition of the PG extract employed. The main ginsenosides reported were Rb1 and Rg1 (content ranging from Rb1 0.023-6.44â¯mg/g and Rg1 0.028-3.21â¯mg/g). Significant modification in blood profile was described in 7 studies, in which 5 studies observed a reduction in total cholesterol, 4 in LDL-cholesterol, and 2 in triacylglycerides. The meta-analysis of 10 studies in volunteers with parameters related with metabolic syndrome describes that PG may induce a mean difference compared to a placebo of -2.30 (95% CI -3.79,-0.80) and -1.47 (95% CI -1.90,-1.05) mg/dL per g/day of PG in the levels of total and LDL-cholesterol, with no significant effects in HDL-cholesterol and triacylglycerides. CONCLUSIONS: PG extract may induce an improvement in blood lipid profile mainly by a reduction in total and LDL-cholesterol levels.
Subject(s)
Lipids/blood , Panax , Plant Extracts/therapeutic use , Dietary Supplements , Humans , Phytotherapy , Randomized Controlled Trials as Topic , Treatment OutcomeABSTRACT
X-Adrenoleukodystrophy (X-ALD) and its adult-onset, most prevalent variant adrenomyeloneuropathy (AMN) are caused by mutations in the peroxisomal transporter of the very long-chain fatty acid ABCD1. AMN patients classically present spastic paraparesis that can progress over decades, and a satisfactory treatment is currently lacking. Oxidative stress is an early culprit in X-ALD pathogenesis. A combination of antioxidants halts the clinical progression and axonal damage in a murine model of AMN, providing a strong rationale for clinical translation. In this phase II pilot, open-label study, 13 subjects with AMN were administered a high dose of α-tocopherol, N-acetylcysteine, and α-lipoic acid in combination. The primary outcome was the validation of a set of biomarkers for monitoring the biological effects of this and future treatments. Functional clinical scales, the 6-minute walk test (6MWT), electrophysiological studies, and cerebral MRI served as secondary outcomes. Most biomarkers of oxidative damage and inflammation were normalized upon treatment, indicating an interlinked redox and inflammatory homeostasis. Two of the inflammatory markers, MCP1 and 15-HETE, were predictive of the response to treatment. We also observed a significant decrease in central motor conduction time, together with an improvement or stabilization of the 6MWT in 8/10 subjects. This study provides a series of biomarkers that are useful to monitor redox and pro-inflammatory target engagement in future trials, together with candidate biomarkers that may serve for patient stratification and disease progression, which merit replication in future clinical trials. Moreover, the clinical results suggest a positive signal for extending these studies to phase III randomized, placebo-controlled, longer-term trials with the actual identified dose. ClinicalTrials.gov Identifier: NCT01495260.
Subject(s)
Adrenoleukodystrophy/blood , Adrenoleukodystrophy/drug therapy , Antioxidants/administration & dosage , Chemokine CCL2/blood , Hydroxyeicosatetraenoic Acids/blood , Adrenoleukodystrophy/diagnostic imaging , Adult , Biomarkers/blood , Dose-Response Relationship, Drug , Female , Follow-Up Studies , Humans , Inflammation Mediators/antagonists & inhibitors , Inflammation Mediators/blood , Male , Middle Aged , Neural Conduction/drug effects , Neural Conduction/physiology , Pilot Projects , Prospective Studies , Treatment Outcome , Young AdultABSTRACT
OBJECTIVE: This study aimed to characterize the differences in protein oxidation biomarkers in adipose tissue (AT) as an indicator of AT metabolism and bariatric surgery weight-loss success. METHODS: A human model, in which sixty-five individuals with obesity underwent bariatric surgery, and a diet-induced obesity animal model, in which animals were treated for 2 months with normocaloric diets, were analyzed to determine the associations between AT protein oxidation and body weight loss. Protein oxidative biomarkers were determined by gas chromatography/mass spectrometry in AT from human volunteers before the surgery, as well as 2 months after a diet treatment in the animal model. RESULTS: The levels of carboxyethyl-lysine (CEL) and 2-succinocystein (2SC) in both visceral and subcutaneous AT before the surgery directly correlated with greater weight loss in both human and animal models. 2SC levels in subcutaneous AT greater than 4.7 × 106 µmol/mol lysine (95% CI: 3.4 × 106 to 6.0 × 106 ) may predict greater weight loss after bariatric surgery (receiver operating characteristic curve area = 0.8222; P = 0.0047). Additionally, it was observed that individuals with diabetes presented lower levels of CEL and 2SC in subcutaneous AT (P = 0.0266 and P = 0.0316, respectively) compared with individuals without diabetes. CONCLUSIONS: CEL and 2SC in AT are useful biomarkers of AT metabolism and predict the individual's ability to reduce body weight after bariatric surgery.
Subject(s)
Adipose Tissue/metabolism , Bariatric Surgery/methods , Biomarkers/metabolism , Obesity/therapy , Proteins/metabolism , Weight Loss/physiology , Adult , Aged , Animals , Disease Models, Animal , Female , Glycosylation , Humans , Male , Mice , Middle Aged , Oxidation-Reduction , Young AdultABSTRACT
Introducción: Entre los principales componentes lipídicos de las membranas celulares se encuentran los glicerofosfolípidos, que se sintetizan en una vía de novo a partir del diacilglicerol (DAG). El perfil lipídico es una característica optimizada asociada con la longevidad animal. En este contexto, hipotetizamos que la tasa de biosíntesis de DAG y, por extensión, de glicerofosfolípidos, guarda una relación con la longevidad de una especie animal. Material y métodos: Se realiza un análisis lipidómico basado en espectrometría de masas del plasma de 11 especies de mamíferos que cubren un rango de longevidad máxima de 3,5 a 120 años. La identificación de especies lipídicas se basa en masa exacta, tiempo de retención y distribución isotópica. Se aplica un test ANOVA para obtener las especies lipídicas diferenciales entre las especies y la correlación de Spearman para establecer su asociación con la longevidad. Los análisis estadísticos se realizaron con el programa SPSS y el software para el análisis metabolómico MetaboAnalyst. Resultados: Entre las 1.061 especies moleculares lipídicas diferenciales se identifican 47DAG, 14 de los cuales presentan una correlación significativa y negativa con la longevidad animal. El análisis multivariante muestra que solamente con estos 14DAG somos capaces de discriminar una especie animal y su longevidad máxima. Conclusiones: Estos resultados indican que las especies longevas tienen una menor tasa de biosíntesis de novo de glicerofosfolípidos, posiblemente asociada a una menor tasa de recambio de los lípidos de membrana, lo que conllevaría un menor coste energético
Background: The glycerophospholipids, synthesised from diacylglycerol (DAG), are one of the main lipid components of cell membranes. The lipid profile is an optimised feature associated with animal longevity. In this context, the hypothesis is presented that the DAG biosynthesis rate, and thus, the glycerophospholipids content, is related to animal longevity. Material and methods: A plasma lipidomic analysis was performed based on the mass spectrometry of 11 mammalian species with a maximum longevity ranging from 3.5 to 120 years. Lipid identification was based on exact mass, retention time, and isotopic distribution. ANOVA test was applied to differentiate the lipids between animal species. The relationship between these lipids and longevity was carried out with a Spearman correlation. Data was analysed using SPSS and MetaboAnalyst. Results: Among the 1,061 different lipid molecular species found between species, 47 were defined as DAG. Interestingly, 14 of them showed a negative correlation with mammalian maximum longevity. Multivariate statistics revealed that 14 DAGs were enough to define mammalian species and their maximum longevity. Conclusions: Data suggest that long-lived mammalian species have a lower rate of glycerophospholipids synthesis through the de novo pathway, possibly associated with a lower rate of membrane lipid exchange, which in turn is related to lower energy expenditure
Subject(s)
Animals , Glycerophospholipids/biosynthesis , Longevity/physiology , Mammals/metabolismABSTRACT
BACKGROUND: The glycerophospholipids, synthesised from diacylglycerol (DAG), are one of the main lipid components of cell membranes. The lipid profile is an optimised feature associated with animal longevity. In this context, the hypothesis is presented that the DAG biosynthesis rate, and thus, the glycerophospholipids content, is related to animal longevity. MATERIAL AND METHODS: A plasma lipidomic analysis was performed based on the mass spectrometry of 11 mammalian species with a maximum longevity ranging from 3.5 to 120 years. Lipid identification was based on exact mass, retention time, and isotopic distribution. ANOVA test was applied to differentiate the lipids between animal species. The relationship between these lipids and longevity was carried out with a Spearman correlation. Data was analysed using SPSS and MetaboAnalyst. RESULTS: Among the 1,061 different lipid molecular species found between species, 47 were defined as DAG. Interestingly, 14 of them showed a negative correlation with mammalian maximum longevity. Multivariate statistics revealed that 14 DAGs were enough to define mammalian species and their maximum longevity. CONCLUSIONS: Data suggest that long-lived mammalian species have a lower rate of glycerophospholipids synthesis through the de novo pathway, possibly associated with a lower rate of membrane lipid exchange, which in turn is related to lower energy expenditure.
Subject(s)
Glycerophospholipids/biosynthesis , Longevity/physiology , Mammals/metabolism , AnimalsABSTRACT
Aging is a multifactorial process which affects all animals. Aging as a result of damage accumulation is the most accepted explanation but the proximal causes remain to be elucidated. There is also evidence indicating that aging has an important genetic component. Animal species age at different rates and specific signaling pathways, such as insulin/insulin-like growth factor, can regulate life span of individuals within a species by reprogramming cells in response to environmental changes. Here, we use an unbiased approach to identify novel factors that regulate life span in Drosophila melanogaster. We compare the transcriptome and metabolome of two wild-type strains used widely in aging research: short-lived Dahomey and long-lived Oregon R flies. We found that Dahomey flies carry several traits associated with short-lived individuals and species such as increased lipoxidative stress, decreased mitochondrial gene expression, and increased Target of Rapamycin signaling. Dahomey flies also have upregulated octopamine signaling known to stimulate foraging behavior. Accordingly, we present evidence that increased foraging behavior, under laboratory conditions where nutrients are in excess increases damage generation and accelerates aging. In summary, we have identified several new pathways, which influence longevity highlighting the contribution and importance of the genetic component of aging.
Subject(s)
Aging/genetics , Aging/physiology , Drosophila melanogaster/genetics , Drosophila melanogaster/physiology , Animals , Gene Expression , Longevity/genetics , Longevity/physiology , Metabolome/genetics , Metabolome/physiology , Oxidative Stress/genetics , Oxidative Stress/physiology , Phenotype , Signal Transduction/genetics , Signal Transduction/physiology , Transcriptome/genetics , Transcriptome/physiologyABSTRACT
Oxidative damage and inflammation coexist in healthy human brain aging. The present study analyzes levels of protein adduction by lipid peroxidation (LP) end-products neuroketal (NKT) and malondialdehyde (MDA), as markers of protein oxidative damage, cycloxygenase-2 (COX-2) levels, as a marker of inflammation, and cytochrome P450 2J2 (CYP2J2), responsible of generation of neuroprotective products, in twelve brain regions in normal middle-aged individuals (MA) and old-aged (OA) individuals. In addition, levels of these markers were evaluated as a function of age as a continuous variable and correction for multiple comparisons. Selection of regions was based on their different vulnerability to prevalent neurodegenerative diseases in aging. Our findings show region-dependent LP end-products, COX-2 and CYP2J2 changes in the aging human brain. However, no clear relationship can be established between NKT, MDA, COX-2 and CYP2J2 levels, and regional vulnerability to neurodegeneration in old age.
Subject(s)
Aging/metabolism , Brain/metabolism , Brain/pathology , Lipid Peroxidation , Oxidative Stress , Adult , Aged , Blotting, Western , Cytochrome P-450 CYP2J2 , Cytochrome P-450 Enzyme System/metabolism , Female , Humans , Inflammation/metabolism , Male , Malondialdehyde/metabolism , Middle AgedABSTRACT
The nuclear factor erythroid 2-like 2 (NRF2) is the master regulator of endogenous antioxidant responses. Oxidative damage is a shared and early-appearing feature in X-linked adrenoleukodystrophy (X-ALD) patients and the mouse model (Abcd1 null mouse). This rare neurometabolic disease is caused by the loss of function of the peroxisomal transporter ABCD1, leading to an accumulation of very long-chain fatty acids and the induction of reactive oxygen species of mitochondrial origin. Here, we identify an impaired NRF2 response caused by aberrant activity of GSK-3ß. We find that GSK-3ß inhibitors can significantly reactivate the blunted NRF2 response in patients' fibroblasts. In the mouse models (Abcd1- and Abcd1-/Abcd2-/- mice), oral administration of dimethyl fumarate (DMF/BG12/Tecfidera), an NRF2 activator in use for multiple sclerosis, normalized (i) mitochondrial depletion, (ii) bioenergetic failure, (iii) oxidative damage, and (iv) inflammation, highlighting an intricate cross-talk governing energetic and redox homeostasis in X-ALD Importantly, DMF halted axonal degeneration and locomotor disability suggesting that therapies activating NRF2 hold therapeutic potential for X-ALD and other axonopathies with impaired GSK-3ß/NRF2 axis.
Subject(s)
Adrenoleukodystrophy/drug therapy , Antioxidants/therapeutic use , Dimethyl Fumarate/therapeutic use , Glycogen Synthase Kinase 3 beta/metabolism , NF-E2-Related Factor 2/metabolism , ATP Binding Cassette Transporter, Subfamily D, Member 1/genetics , Adrenoleukodystrophy/metabolism , Animals , Anti-Inflammatory Agents/therapeutic use , Dimethyl Fumarate/administration & dosage , Disease Models, Animal , Gliosis/drug therapy , Humans , Male , Mice , Mice, Knockout , Organelle Biogenesis , Oxidative Stress/physiology , Proto-Oncogene Proteins c-akt/metabolism , Reactive Oxygen Species/metabolismABSTRACT
PURPOSE: In this work, a non-targeted approach was used to unravel changes in the plasma lipidome of PCOS patients. The aim is to offer new insights in PCOS patients strictly selected in order to avoid confounding factors such as dyslipemia, obesity, altered glucose/insulin metabolism, cardiovascular disease, or cancer. RESULTS: Multivariate statistics revealed a specific lipidomic signature for PCOS patients without associated pathologies. This signature implies changes, mainly by down-regulation, in glycerolipid, glycerophospholipid and sphingolipid metabolism suggesting an altered biosynthetic pathway of glycerophospholipids and cell signaling as second messengers in women with PCOS. CONCLUSIONS: Our study confirms that a lipidomic approach discriminates a specific phenotype from PCOS women without associated pathologies from healthy controls. METHODS: In a cross-sectional pilot study, data were obtained from 34 subjects, allocated to one of two groups: a) lean, healthy controls (n = 20), b) PCOS patients (n = 14) with diagnosis based on hyperandrogenaemia, oligo-anovulation and abnormal ovaries with small follicular cysts. A detailed biochemical characterization was made and lipidomic profiling was performed via an untargeted approach using LC-ESI-QTOF MS/MS.
ABSTRACT
Fatty acids are key components in the structural diversity of lipids and play a strategic role in the functional properties of lipids which determine the structural and functional integrity of neural cell membranes, the generation of lipid signaling mediators, and the chemical reactivity of acyl chains. The present study analyzes the profile of lipid fatty acid composition of membranes of human frontal cortex area 8 in individuals ranging from 40 to 90 years old. Different components involved in polyunsaturated fatty acid biosynthesis pathways, as well as adaptive defense mechanisms involved in the lipid-mediated modulation of inflammation, are also assessed. Our results show that the lipid profile in human frontal cortex is basically preserved through the adult life span to decay at advanced ages, which is accompanied by an adaptive proactive anti-inflammatory response possibly geared to ensuring cell survival and function.
Subject(s)
Aging/metabolism , Fatty Acids/metabolism , Frontal Lobe/metabolism , Adult , Aged , Aged, 80 and over , Blotting, Western , Cadaver , Chromatography, Gas , Humans , Inflammation/metabolism , Longevity , Middle Aged , Polymerase Chain ReactionABSTRACT
Sirtuin 2 (SIRT2) is a member of a family of NAD+ -dependent histone deacetylases (HDAC) that play diverse roles in cellular metabolism and especially for aging process. SIRT2 is located in the nucleus, cytoplasm, and mitochondria, is highly expressed in the central nervous system (CNS), and has been reported to regulate a variety of processes including oxidative stress, genome integrity, and myelination. However, little is known about the role of SIRT2 in the nervous system specifically during aging. Here, we show that middle-aged, 13-month-old mice lacking SIRT2 exhibit locomotor dysfunction due to axonal degeneration, which was not present in young SIRT2 mice. In addition, these Sirt2-/- mice exhibit mitochondrial depletion resulting in energy failure, and redox dyshomeostasis. Our results provide a novel link between SIRT2 and physiological aging impacting the axonal compartment of the central nervous system, while supporting a major role for SIRT2 in orchestrating its metabolic regulation. This underscores the value of SIRT2 as a therapeutic target in the most prevalent neurodegenerative diseases that undergo with axonal degeneration associated with redox and energetic dyshomeostasis.